Mei Pharma Inc (MEIP) 6.82 $MEIP
Metastatic Prostate Cancer - Pipeline Review, H1 2014: 9 Companies and 16 Drugs Profiled
M2 - Mon May 12, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f52w3s/metastatic) has announced the addition of the "Metastatic Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agonox - Camurus AB - Colby Pharmaceutical Company - Fountain Biopharma Inc. - MEI Pharma, Inc. - OXiGENE, Inc. - Progenics Pharmaceuticals, Inc. Drug Profiles: - cabazitaxel - pracinostat - leuprolide acetate - LU-901 - veliparib - Engineered Autologous T Cells [cyclophosphamide] - MEDI-6469 - CPC-410 - Actimab-P - Peptide to Inhibit MT1 MMP for Autoimmune Disorders, Inflammation and Oncology - MIP-1095 - FB-704A - Ceramide Analogs - KGP-94 - Vaccine For Oncolytic Newcastle Disease Virus - Glutathione Disulfide Liposomal For more information visit http://www.researchandmarkets.com/research/f52w3s/metastatic
MEI Pharma to Present at Bank of America Merrill Lynch and UBS Healthcare Conferences
PR Newswire - Thu May 08, 8:00AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:
Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7chq8b/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Amgen Inc. - Boehringer Ingelheim GmbH - California Stem Cell, Inc. - Cell Therapeutics, Inc. - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Daiichi Sankyo Company, Limited - EGEN, Inc. - Eli Lilly and Company - GlaxoSmithKline plc - ImmunoGen, Inc. - Immunovaccine, Inc. - Incyte Corporation - Lee's Pharmaceutical Holdings Limited - MEI Pharma, Inc. - MabVax Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OncoMed Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Oxford BioMedica plc - Pharma Mar, S.A. - Pharmacyclics, Inc. - Recepta Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRION Pharma GmbH Drug Profiles: - pazopanib hydrochloride - trebananib - paclitaxel poliglumex - paclitaxel - MEK-162 - idronoxil - trabectedin - alisertib - dalantercept - elesclomol - TroVax - ramucirumab - pelareorep - nintedanib - catumaxomab - CRLX-101 - VTX-2337 - gimatecan - exatecan mesylate - RebmAb-100 - EGEN-001 - NSC-748933 - INCB-24360 - birinapant - rucaparib - metformin - Cancer Stem Cell Therapy - DPX-Survivac - ganetespib - pralatrexate For more information visit http://www.researchandmarkets.com/research/7c...opian_tube
Arthritis - Pipeline Review, H1 2014 - Includes 38 Company and 68 Drug Profiles
M2 - Wed May 07, 8:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3sblwf/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AngioLab, Inc - Astellas Pharma Inc. - AstraZeneca PLC - Bone Medical Limited - Bristol-Myers Squibb Company - CSL Limited - CalciMedica, Inc. - Can-Fite BioPharma Ltd. - Eisai Co., Ltd. - Elan Corporation, plc - Endocyte, Inc. - Georgia Tech Research Corporation - GlaxoSmithKline plc - Lexicon Pharmaceuticals, Inc. - MEI Pharma, Inc. - NasVax Ltd. - Oscotec Inc. - PLx Pharma Inc. - SelectX Pharmaceuticals, Inc. - Sylentis S.A. - Taisho Pharmaceutical Co., Ltd. - Taiwan Liposome Company, Ltd. - Teva Pharmaceutical Industries Limited - TheraKine Ltd. - Viron Therapeutics, Inc. - WhanIn Pharmaceutical Co., Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/3sblwf/arthritis
MEI Pharma Initiates Clinical Study Of Mitochondrial Inhibitor Drug Candidate ME-344 In Small Cell Lung And Ovarian Cancers
PR Newswire - Mon May 05, 8:00AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patient has been dosed in a Phase Ib clinical study of its investigational mitochondrial inhibitor drug candidate ME-344 in combination with Hycamtin® (topotecan) in patients with solid tumors, including small cell lung and ovarian cancers. The open-label study is expected to enroll up to 64 patients with preliminary data anticipated by the first quarter of 2015.
Global Peritoneal Tumor Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t7vbm9/peritoneal_tumor) has announced the addition of the "Peritoneal Tumor - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peritoneal Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Tumor and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Peritoneal Tumor - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peritoneal Tumor and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peritoneal Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Latest news and deals relating related to pipeline products Companies Mentioned - Boehringer Ingelheim GmbH - Amgen Inc. - Eli Lilly and Company - Cell Therapeutics, Inc. - MEI Pharma, Inc. - Recepta Biopharma S.A. - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/t7...neal_tumor
MEI Pharma Adds Former VC David Urso as Senior Vice President of Corporate Development and General Counsel
PR Newswire - Tue Apr 08, 7:30AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today the appointment of David Urso as Senior Vice President of Corporate Development and General Counsel. Mr. Urso joins MEI Pharma with more than two decades of experience in the life science industry, most recently as Chief Operating Officer and General Counsel at Tioga Pharmaceuticals, a company he co-founded in 2005 as a Principal at Forward Ventures.
MEI Pharma Identifies Potential Biomarker For Pracinostat In Bladder Cancer
PR Newswire - Mon Apr 07, 7:30AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced the presentation of new pre-clinical data showing the ability of its lead drug candidate Pracinostat to inhibit bladder cancer cell growth and induce activated transcription factor 3 (ATF-3) expression, a potential marker of tumor response. The data were presented yesterday at the American Association for Cancer Research (AACR) Annual Meeting in San Diego.
MEI Pharma To Present At Needham Healthcare Conference
PR Newswire - Tue Apr 01, 8:00AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Needham Healthcare Conference on Tuesday, April 8, 2014 at 3:00 p.m. Eastern time from the Westin Grand Central Hotel in New York City. A live webcast of the presentation can be accessed at www.meipharma.com. A replay will be available approximately one hour after the presentation.
MEI Pharma, Inc. (MEIP) in Focus: Stock up 12.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 7:44AM CDT
MEI Pharma, Inc. was a big mover last session, as the company saw its shares rise over 12% on the day.
Nasdaq stocks posting largest percentage increases
AP - Thu Mar 27, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
3 Stocks Spiking on Big Volume
at The Street - Thu Mar 27, 8:11AM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
MEI Pharma (MEIP) Crumbles: Stock Falls by 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 7:53AM CDT
MEI Pharma, Inc. (MEIP) saw a big move last session, reversing the recent trend for MEIP as the stock is now up around 17.2% in the past one-month time frame.
4 Stocks Under $10 Triggering Breakouts
at The Street - Fri Mar 07, 5:00AM CST
These under-$10 stocks are within range of triggering breakout trades.
MEI Pharma (MEIP) is Overbought, What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:21AM CST
MEI Pharma (MEIP) is Overbought, What’s Next?
MEI Pharma Receives Orphan Status For Lead Drug Candidate Pracinostat For Treatment Of Acute Myeloid Leukemia
PR Newswire - Fri Feb 28, 7:33AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's investigational drug Pracinostat for the treatment of acute myeloid leukemia (AML).
MEI Pharma To Present At Cowen Health Care And ROTH Conferences
PR Newswire - Tue Feb 25, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:
Evidera And Symphony Technology Group Announce Appointment Of Simon Kennedy To Senior Leadership Roles
PR Newswire - Tue Feb 11, 8:00AM CST
Evidera, a leading provider of evidence-based solutions for the healthcare industry, and Symphony Technology Group (STG) (STG), a strategic private equity firm, today announced that Simon Kennedy has joined Evidera as executive chairman of the board, effective January 1. In this position, he plays a leadership role in defining Evidera's acquisition, new product development and overall growth strategies, working closely with Evidera's management team. Kennedy has also joined STG as healthcare operations partner, and another portfolio company, Symphony Health Solutions, as a member of the board of directors.
5 Stocks Ready to Break Out
at The Street - Fri Jan 31, 12:59PM CST
These stocks look ready to break out and trade higher from current levels.
Metastatic Prostate Cancer - Pipeline Review, H1 2014: 9 Companies and 16 Drugs Profiled
M2 - Mon May 12, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f52w3s/metastatic) has announced the addition of the "Metastatic Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agonox - Camurus AB - Colby Pharmaceutical Company - Fountain Biopharma Inc. - MEI Pharma, Inc. - OXiGENE, Inc. - Progenics Pharmaceuticals, Inc. Drug Profiles: - cabazitaxel - pracinostat - leuprolide acetate - LU-901 - veliparib - Engineered Autologous T Cells [cyclophosphamide] - MEDI-6469 - CPC-410 - Actimab-P - Peptide to Inhibit MT1 MMP for Autoimmune Disorders, Inflammation and Oncology - MIP-1095 - FB-704A - Ceramide Analogs - KGP-94 - Vaccine For Oncolytic Newcastle Disease Virus - Glutathione Disulfide Liposomal For more information visit http://www.researchandmarkets.com/research/f52w3s/metastatic
MEI Pharma to Present at Bank of America Merrill Lynch and UBS Healthcare Conferences
PR Newswire - Thu May 08, 8:00AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:
Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7chq8b/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Amgen Inc. - Boehringer Ingelheim GmbH - California Stem Cell, Inc. - Cell Therapeutics, Inc. - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Daiichi Sankyo Company, Limited - EGEN, Inc. - Eli Lilly and Company - GlaxoSmithKline plc - ImmunoGen, Inc. - Immunovaccine, Inc. - Incyte Corporation - Lee's Pharmaceutical Holdings Limited - MEI Pharma, Inc. - MabVax Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OncoMed Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Oxford BioMedica plc - Pharma Mar, S.A. - Pharmacyclics, Inc. - Recepta Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRION Pharma GmbH Drug Profiles: - pazopanib hydrochloride - trebananib - paclitaxel poliglumex - paclitaxel - MEK-162 - idronoxil - trabectedin - alisertib - dalantercept - elesclomol - TroVax - ramucirumab - pelareorep - nintedanib - catumaxomab - CRLX-101 - VTX-2337 - gimatecan - exatecan mesylate - RebmAb-100 - EGEN-001 - NSC-748933 - INCB-24360 - birinapant - rucaparib - metformin - Cancer Stem Cell Therapy - DPX-Survivac - ganetespib - pralatrexate For more information visit http://www.researchandmarkets.com/research/7c...opian_tube
Arthritis - Pipeline Review, H1 2014 - Includes 38 Company and 68 Drug Profiles
M2 - Wed May 07, 8:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3sblwf/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AngioLab, Inc - Astellas Pharma Inc. - AstraZeneca PLC - Bone Medical Limited - Bristol-Myers Squibb Company - CSL Limited - CalciMedica, Inc. - Can-Fite BioPharma Ltd. - Eisai Co., Ltd. - Elan Corporation, plc - Endocyte, Inc. - Georgia Tech Research Corporation - GlaxoSmithKline plc - Lexicon Pharmaceuticals, Inc. - MEI Pharma, Inc. - NasVax Ltd. - Oscotec Inc. - PLx Pharma Inc. - SelectX Pharmaceuticals, Inc. - Sylentis S.A. - Taisho Pharmaceutical Co., Ltd. - Taiwan Liposome Company, Ltd. - Teva Pharmaceutical Industries Limited - TheraKine Ltd. - Viron Therapeutics, Inc. - WhanIn Pharmaceutical Co., Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/3sblwf/arthritis
MEI Pharma Initiates Clinical Study Of Mitochondrial Inhibitor Drug Candidate ME-344 In Small Cell Lung And Ovarian Cancers
PR Newswire - Mon May 05, 8:00AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patient has been dosed in a Phase Ib clinical study of its investigational mitochondrial inhibitor drug candidate ME-344 in combination with Hycamtin® (topotecan) in patients with solid tumors, including small cell lung and ovarian cancers. The open-label study is expected to enroll up to 64 patients with preliminary data anticipated by the first quarter of 2015.
Global Peritoneal Tumor Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t7vbm9/peritoneal_tumor) has announced the addition of the "Peritoneal Tumor - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peritoneal Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Tumor and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Peritoneal Tumor - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peritoneal Tumor and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peritoneal Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Latest news and deals relating related to pipeline products Companies Mentioned - Boehringer Ingelheim GmbH - Amgen Inc. - Eli Lilly and Company - Cell Therapeutics, Inc. - MEI Pharma, Inc. - Recepta Biopharma S.A. - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/t7...neal_tumor
MEI Pharma Adds Former VC David Urso as Senior Vice President of Corporate Development and General Counsel
PR Newswire - Tue Apr 08, 7:30AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today the appointment of David Urso as Senior Vice President of Corporate Development and General Counsel. Mr. Urso joins MEI Pharma with more than two decades of experience in the life science industry, most recently as Chief Operating Officer and General Counsel at Tioga Pharmaceuticals, a company he co-founded in 2005 as a Principal at Forward Ventures.
MEI Pharma Identifies Potential Biomarker For Pracinostat In Bladder Cancer
PR Newswire - Mon Apr 07, 7:30AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced the presentation of new pre-clinical data showing the ability of its lead drug candidate Pracinostat to inhibit bladder cancer cell growth and induce activated transcription factor 3 (ATF-3) expression, a potential marker of tumor response. The data were presented yesterday at the American Association for Cancer Research (AACR) Annual Meeting in San Diego.
MEI Pharma To Present At Needham Healthcare Conference
PR Newswire - Tue Apr 01, 8:00AM CDT
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Needham Healthcare Conference on Tuesday, April 8, 2014 at 3:00 p.m. Eastern time from the Westin Grand Central Hotel in New York City. A live webcast of the presentation can be accessed at www.meipharma.com. A replay will be available approximately one hour after the presentation.
MEI Pharma, Inc. (MEIP) in Focus: Stock up 12.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 7:44AM CDT
MEI Pharma, Inc. was a big mover last session, as the company saw its shares rise over 12% on the day.
Nasdaq stocks posting largest percentage increases
AP - Thu Mar 27, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
3 Stocks Spiking on Big Volume
at The Street - Thu Mar 27, 8:11AM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
MEI Pharma (MEIP) Crumbles: Stock Falls by 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 7:53AM CDT
MEI Pharma, Inc. (MEIP) saw a big move last session, reversing the recent trend for MEIP as the stock is now up around 17.2% in the past one-month time frame.
4 Stocks Under $10 Triggering Breakouts
at The Street - Fri Mar 07, 5:00AM CST
These under-$10 stocks are within range of triggering breakout trades.
MEI Pharma (MEIP) is Overbought, What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:21AM CST
MEI Pharma (MEIP) is Overbought, What’s Next?
MEI Pharma Receives Orphan Status For Lead Drug Candidate Pracinostat For Treatment Of Acute Myeloid Leukemia
PR Newswire - Fri Feb 28, 7:33AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's investigational drug Pracinostat for the treatment of acute myeloid leukemia (AML).
MEI Pharma To Present At Cowen Health Care And ROTH Conferences
PR Newswire - Tue Feb 25, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:
Evidera And Symphony Technology Group Announce Appointment Of Simon Kennedy To Senior Leadership Roles
PR Newswire - Tue Feb 11, 8:00AM CST
Evidera, a leading provider of evidence-based solutions for the healthcare industry, and Symphony Technology Group (STG) (STG), a strategic private equity firm, today announced that Simon Kennedy has joined Evidera as executive chairman of the board, effective January 1. In this position, he plays a leadership role in defining Evidera's acquisition, new product development and overall growth strategies, working closely with Evidera's management team. Kennedy has also joined STG as healthcare operations partner, and another portfolio company, Symphony Health Solutions, as a member of the board of directors.
5 Stocks Ready to Break Out
at The Street - Fri Jan 31, 12:59PM CST
These stocks look ready to break out and trade higher from current levels.
